Abbott Laboratories (ABT) Net Income towards Common Stockholders (2009 - 2026)

Abbott Laboratories has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $928.0 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 47.84% year-over-year to $928.0 million; the TTM figure through Jun 2026 stood at $5.4 billion (down 61.19% YoY), while the FY2025 annual figure was $6.5 billion, down 51.32% from the prior year.
• Net Income towards Common Stockholders came in at $928.0 million for Q2 2026 at Abbott Laboratories, down from $1.1 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $9.2 billion in Q4 2024 to a low of $928.0 million in Q2 2026.
• Average Net Income towards Common Stockholders over 5 years is $1.9 billion, with a median of $1.4 billion recorded in 2022.
• Year-over-year, Net Income towards Common Stockholders surged 478.98% in 2024 and plunged 80.76% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $1.0 billion in 2022, then jumped by 54.31% to $1.6 billion in 2023, then surged by 478.98% to $9.2 billion in 2024, then sank by 80.76% to $1.8 billion in 2025, then sank by 47.75% to $928.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $928.0 million in Q2 2026, $1.1 billion in Q1 2026, and $1.8 billion in Q4 2025.